Lundbeck Canada hails new national standard on psychological health and safety in the workplace

Lundbeck Canada hails new national standard on psychological health and safety 
in the workplace 
TORONTO, Jan. 16, 2013 /CNW/ - Lundbeck Canada, a leading provider of 
medications for treating mental illness, today expressed its strong support 
for the new national standard on psychological health and safety in the 
"Prevention is always the best way of reducing possible harm," said Patrick 
Cashman, President of Lundbeck Canada. "Establishing this clear, tangible 
approach to help Canada's employers better protect the mental health of their 
team members is an extremely important and positive step forward." 
The National Standard of Canada on Psychological Health and Safety in the 
Workplace is voluntary, however it includes explicit requirements for 
development of a psychological health and safety management plan, identifying 
situations or processes which could present risks to psychological health, and 
ensuring that employees are connected to services or resources to help deal 
with mental illness. 
"Steel-toed boots and other measures to protect the physical health of 
employees are viewed as a given in Canadian workplaces; it's imperative that 
mental and psychological health be viewed in an equally important way," said 
"Better protecting the mental well-being of our country's workforce benefits 
all Canadians through better productivity, lower health care costs and having 
healthier, happier people driving our economy." 
As a company dedicated to constantly improving the quality of lives of people 
who live with mental illness, Lundbeck Canada has put measures in place aimed 
at maintaining and improving the mental well-being of its employees. Flexible 
work hours, the ability to work from home and an annual $500.00 benefit per 
employee to direct towards any activity that contributes to psychological or 
physical well-being (e.g. yoga classes, gym membership, photography classes) 
are all offered to help Lundbeck Canada employees reduce stress and maintain 
good mental health through an optimal work-life balance 
A division of the Denmark-based pharmaceutical maker H. Lundbeck A/S, Lundbeck 
Canada Inc. has been a trusted source of innovative treatments for Canadians 
since 1995 with headquarters in Montreal. Originally focused on providing 
products for the treatment of depression, anxiety, Alzheimer's disease and 
schizophrenia, Lundbeck Canada now offers cancer therapies for the treatment 
of chronic lymphocytic leukemia and non-Hodgkin lymphoma. Lundbeck's 
Celexa® and Cipralex ® are two of the most widely used anti-depressants 
prescribed by Canadian doctors. A patient-focused partner in Canadian health 
care, Lundbeck Canada's mission is to improve the quality of life of people 
suffering from Central Nervous System disorders and cancer. 
Globally, Lundbeck was ranked #1 in a 2012 global survey by PatientView that 
evaluated the ability of pharmaceutical companies to meet patient 
expectations. In the survey, Lundbeck also took top honours in "best at 
providing high-quality information to patients" and "best at being transparent 
with external stakeholders". 
Daniel McCarthy, Senior Director, External Relations Lundbeck Canada Inc. Phone (514) 501.6381 
Ashley Curran, Senior Account Manager Veritas Communications 647-967-1349 
SOURCE: Lundbeck Canada Inc 
To view this news release in HTML formatting, please use the following URL: 
CO: Lundbeck Canada Inc
ST: Ontario
-0- Jan/16/2013 15:00 GMT
Press spacebar to pause and continue. Press esc to stop.